CJC-1295 Complete Guide: With DAC vs. Without DAC, Dosing, Stacking with Ipamorelin (2026)

If you've spent any time researching growth hormone optimization, you've almost certainly come across CJC-1295. It's one of the most widely studied and clinically referenced GHRH analogs available today — and for good reason. Whether you want to understand the science behind it, compare the two main variants (with and without DAC), or find a reliable stacking protocol with Ipamorelin, this guide covers everything.

What Is CJC-1295?

CJC-1295 is a synthetic, 30-amino-acid peptide analog of growth hormone-releasing hormone (GHRH). It was developed to mimic the action of the body's endogenous GHRH while overcoming one of its primary limitations: a very short half-life of just a few minutes due to rapid degradation by plasma proteases.

The original GHRH(1-29) fragment — sometimes called Sermorelin — provided a template, but CJC-1295 takes this further with four strategic amino acid substitutions at positions 2, 8, 15, and 27. These substitutions protect the peptide from dipeptidyl peptidase IV (DPP-IV) and other proteolytic enzymes, extending its active window substantially.

The result is a peptide that binds to GHRH receptors on pituitary somatotroph cells with high affinity and selectivity, stimulating the synthesis and pulsatile release of growth hormone (GH) and, downstream, insulin-like growth factor 1 (IGF-1).

Mechanism of Action

When CJC-1295 binds to the GHRH receptor on somatotroph cells in the anterior pituitary, it activates a G-protein coupled signaling pathway. This increases intracellular cyclic AMP (cAMP) and activates protein kinase A (PKA), which ultimately causes secretory vesicles containing growth hormone to fuse with the cell membrane and release their contents into circulation.

Critically, CJC-1295 does not override the body's natural GH regulatory mechanisms. Somatostatin — the inhibitory hormone that "brakes" GH pulses — still functions normally. This means CJC-1295 amplifies and sustains the body's own pulsatile GH release pattern rather than producing a constant, flat elevation — an important distinction with implications for both safety and efficacy.

CJC-1295 With DAC vs. Without DAC: A Critical Difference

The most important thing to understand about CJC-1295 is that there are two fundamentally different versions, and they behave very differently in the body.

CJC-1295 With DAC

DAC stands for Drug Affinity Complex — a reactive lysine residue modification added to the C-terminus of the peptide. Within minutes of injection, this reactive group covalently bonds to serum albumin, the most abundant plasma protein in the blood. Since albumin has a circulating half-life of roughly 20 days, it essentially tethers the peptide to a long-lived carrier protein.

The result: CJC-1295 with DAC has an estimated half-life of 5.8 to 8.1 days in humans. A single injection produces sustained GH and IGF-1 elevation for up to 14 days. Clinical research published in the Journal of Clinical Endocrinology & Metabolism demonstrated dose-dependent increases in mean plasma GH concentrations by 2- to 10-fold for six or more days, and mean plasma IGF-I concentrations by 1.5- to 3-fold for 9–11 days following a single dose.

Release pattern: CJC-1295 with DAC creates what researchers describe as a "GH bleed" — a sustained elevation in baseline GH and IGF-1 that persists between pulses. Basal GH levels can increase up to 7.5-fold, with natural pulsatile peaks riding on top of this elevated baseline.

Dosing frequency: Once or twice per week subcutaneous injection is typical. Common research-referenced doses range from 1 to 2 mg per week.

CJC-1295 Without DAC (Mod GRF 1-29)

The version without the DAC modification — often labeled as Modified GRF 1-29 (Mod GRF 1-29) — retains the four protective amino acid substitutions but lacks the albumin-binding group. Without the albumin anchor, it circulates freely and is cleared relatively quickly, with a functional half-life of approximately 20 to 30 minutes.

Each injection produces a sharp, discrete GHRH pulse that triggers a significant GH spike. This spike peaks roughly 15–30 minutes post-injection and resolves within 2–3 hours — closely mimicking the body's natural GH pulse pattern.

Release pattern: Distinct, time-limited GH pulses rather than sustained elevation. This is preferred by those who want to preserve the natural pulsatile rhythm of GH secretion and avoid continuous baseline elevation.

Dosing frequency: Because of its short active window, Mod GRF 1-29 is typically dosed 2–3 times daily to maintain meaningful GH stimulation throughout the day. The most common timing is upon waking, post-workout, and before bed.

Quick Comparison

Benefits of CJC-1295

The downstream effects of elevated GH and IGF-1 from CJC-1295 administration — as documented in clinical and preclinical research — include:

• Improved body composition: Increased lean muscle mass and reduced adipose tissue. GH directly stimulates lipolysis (fat breakdown) and supports protein synthesis. Clinical observations have noted reductions in body fat percentage over sustained use.
• Enhanced muscle recovery and tissue repair: IGF-1 plays a central role in muscle satellite cell activation and tissue regeneration. Users and clinicians report faster recovery from exercise and injury.
• Deeper, more restorative sleep: GH is predominantly secreted during slow-wave (deep) sleep. Higher GH pulsatility is associated with improved sleep architecture — many users report deeper sleep within the first weeks of use.
• Improved energy and vitality: Optimized GH/IGF-1 levels support mitochondrial function, metabolic efficiency, and subjective energy levels, particularly in those with age-related GH decline.
• Skin and connective tissue quality: IGF-1 supports collagen synthesis and skin elasticity; improvements in skin texture are commonly reported over multi-month cycles.
• Cognitive support: GH and IGF-1 receptors are present in the brain, and evidence suggests both peptides support neuroplasticity and cognitive function.

Side Effects and Safety Profile

Clinical trials on CJC-1295 reported no serious adverse events. The most commonly reported side effects are mild and transient:

• Injection site reactions: Redness, swelling, or mild pain at the injection site — the most frequently reported effect across studies.
• Vasodilation/flushing: Warmth, mild flushing, or transient reduction in blood pressure shortly after injection. Usually resolves within 30 minutes.
• Headache: Occasionally reported, particularly at higher doses.
• Mild water retention: GH stimulates sodium and water reabsorption; this is dose-dependent and typically resolves with dose reduction.
• Nausea or GI discomfort: Uncommon; more frequently reported in the first week of use.

Contraindications:

• Active malignancy: GH and IGF-1 are growth-promoting signals. CJC-1295 is contraindicated in individuals with known or suspected cancer.
• Uncontrolled diabetes: GH has insulin-antagonizing effects; blood sugar monitoring is essential.
• Severe cardiovascular disease: Use with caution; supervision by a qualified provider is necessary.
• Competitive athletes: CJC-1295 is prohibited under WADA anti-doping regulations.

CJC-1295 Dosing Protocols

CJC-1295 with DAC Protocol

• Dose: 1–2 mg per injection
• Frequency: Once or twice per week
• Administration: Subcutaneous injection (abdomen or thigh)
• Cycle length: 8–12 weeks on, 8–12 weeks off

CJC-1295 Without DAC (Mod GRF 1-29) Protocol

• Dose: 100 mcg per injection
• Frequency: 2–3x daily — upon waking (fasted), post-workout, and 30–60 minutes before bed
• Administration: Subcutaneous injection; rotate sites
• Timing rule: Inject on an empty stomach, or at least 2 hours after a meal — elevated insulin suppresses GH release
• Cycle length: 3–6 months on, 1–2 months off

Stacking CJC-1295 with Ipamorelin: The Gold Standard Protocol

The most clinically referenced and widely used peptide stack in GH optimization is CJC-1295 (without DAC) + Ipamorelin. This combination is considered the gold standard for several important reasons.

CJC-1295 activates the GHRH receptor to trigger GH synthesis and release. Ipamorelin activates the ghrelin receptor (GHS-R1a) — an entirely separate receptor — to amplify the GH pulse through a complementary, additive pathway. When both signals arrive at the pituitary simultaneously, the resulting GH output is substantially greater than either peptide produces alone. Research suggests the synergistic effect can be 5–10 times greater than either compound in isolation.

Ipamorelin's key advantage over older GHRPs (GHRP-2, GHRP-6) is its selectivity. It stimulates GH release without significantly raising cortisol, prolactin, ACTH, or ghrelin. This means fewer side effects, no appetite stimulation, and a cleaner hormonal profile.

Standard CJC-1295/Ipamorelin Stack Protocol

• CJC-1295 (no DAC): 100 mcg per injection
• Ipamorelin: 200–300 mcg per injection
• Frequency: 2–3 injections per day, timed together in the same syringe or sequential injections
• Optimal timing: Upon waking (fasted), post-workout, and 30–60 minutes before sleep
• Critical rule: Inject on an empty stomach. Insulin elevation suppresses GH release and significantly reduces the efficacy of both peptides.
• Cycle structure: 3 months on, 1–2 months off; or a 5-days-on/2-days-off weekly structure

This combination has become the preferred approach in many longevity, anti-aging, and sports medicine practices because it achieves substantial GH pulses while preserving the body's natural pulsatile rhythm — preserving pituitary sensitivity over extended use.

Clinical Research

The foundational human clinical trial for CJC-1295 was published in the Journal of Clinical Endocrinology & Metabolism (Teichman et al., 2006). This randomized, double-blind, placebo-controlled study in healthy adults aged 21–61 demonstrated:

• Dose-dependent GH increases of 2- to 10-fold sustained for 6 or more days after a single injection
• IGF-1 elevation of 1.5- to 3-fold persisting for 9–11 days
• Cumulative IGF-1 increases with multiple doses, remaining above baseline for up to 28 days
• No serious adverse events in any dose group

A second key study (Alba et al., 2006, published in the American Journal of Physiology — Endocrinology and Metabolism) demonstrated that once-daily CJC-1295 administration normalized growth in GHRH-knockout mice, confirming functional pituitary GHRH receptor activation and downstream IGF-1 and growth effects.

A netnographic study in PLOS ONE (2016) analyzed real-world female use of CJC-1295 and documented consistent self-reported improvements in body composition, recovery, and sleep quality — broadly consistent with the GH elevation data from controlled trials.

It is important to note that most formal clinical research predates large-scale phase III trials. The evidence base is promising but not yet fully validated through phase III trials for any specific approved therapeutic indication.

Storage and Reconstitution

• Lyophilized (powder) storage: Refrigerate at 2–8°C. Stable for up to 24 months when properly stored and kept away from light.
• Reconstitution: Add bacteriostatic water (BAC water) slowly down the inside wall of the vial. Do not shake — swirl gently until dissolved.
• Reconstituted solution: Refrigerate immediately; use within 28–30 days. Do not freeze the reconstituted peptide.
• Dosing math example: If you have a 2 mg vial reconstituted with 2 mL BAC water, each 0.1 mL (10 units on an insulin syringe) = 100 mcg.

Frequently Asked Questions

Is CJC-1295 the same as Sermorelin?

No. Both are GHRH analogs targeting the same pituitary receptor, but Sermorelin is the unmodified GHRH(1-29) fragment with a very short half-life (~10 minutes). CJC-1295 includes four stabilizing amino acid substitutions that extend activity significantly, and the DAC variant adds albumin-binding for even greater longevity.

How long until I see results?

Sleep quality improvements are often reported within 1–2 weeks. Meaningful body composition changes typically emerge after 6–12 weeks of consistent use, with the most pronounced effects observed over a full 3–6 month cycle.

Can CJC-1295 be combined with other peptides?

Yes. Beyond Ipamorelin, some protocols add BPC-157 or TB-500 for tissue repair. CJC-1295 works through a GHRH receptor pathway and is generally compatible with peptides that act on different targets.

Is CJC-1295 legal?

CJC-1295 is not FDA-approved as a pharmaceutical product. It has historically been available through compounding pharmacies for physician-prescribed use, though regulatory guidance has been evolving since 2024. Always consult a licensed healthcare provider for current prescribing options in your jurisdiction.

Conclusion

CJC-1295 is one of the most well-researched GHRH analogs available, with documented human safety data, a clear mechanism of action, and meaningful body composition and recovery benefits. The choice between the DAC and no-DAC versions hinges on your desired GH release pattern: sustained elevation versus pulsatile stimulation. When stacked with Ipamorelin — the gold-standard combination — CJC-1295 without DAC offers synergistic, physiological GH amplification without the side effect burden of older GHRPs.

This article is for educational purposes only and does not constitute medical advice. Consult a qualified healthcare provider before beginning any peptide therapy.